Skip to content

Neuroelectrophysiological characteristics of peripheral neuropathy in primary Sjogren's syndrome

Neuroelectrophysiological characteristics of peripheral neuropathy in primary Sjogren's syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015669
Enrollment
Unknown
Registered
2018-04-13
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary Sjogren's syndrome

Interventions

Case series:None

Sponsors

First Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with all of the following conditions will be considered for conclusion: Meeting at least two of the following items: 1. Serum anti-Sjogren syndrome A (anti-SSA)- and/or anti-SSB-positive, or rheumatoid factor positive with serum antinuclear antibody = 1:320; 2. Ocular staining score (OSS) =3; 3. Biopsy of the labial gland showed lymphocyte lesions =1/4 mm2 (at least 50 lymphocyte aggregates within 4mm2 tissue); (1) Presence of sensory, motor, autonomic dysfunction; (2) Aged 30-70 years male and female; (3) Provision of written informed consent.

Exclusion criteria

Exclusion criteria: Patients with one or more of the following conditions will be excluded from this study: 1. A history of external neck, head and face radiation therapy; 2. Sarcoidosis, amyloidosis, graft-versus-host disease, and IgG4-related diseases; 3. Bloodborne diseases; 4. Peripheral neuropathy caused by other diseases; 5. Endocrine disease or other connective tissue diseases; 6. Severe heart, liver, kidney insufficiency, alcoholism or mental illness; 7. Those receiving therapy for abnormal clotting factors and/or anticoagulant therapy; 8. Those present with swelling at the end of the limb; 9. Dermatitis; 10. Poor compliance or refusal to collaborate; 11. Those recently suffering from myocardial infarction; 12. Those taking immunosuppressant; 13. Those wearing a pacemaker or other implantable medical device; 14. Those highly allergic to stimulation; 15. Pregnant woman.

Design outcomes

Primary

MeasureTime frame
Rate of abnormal motor nerve conduction velocity;

Secondary

MeasureTime frame
Rate of abnormal terminal motor latency;Rate of abnormal compound muscle action potential amplitude;Rate of sensory nerve conduction velocity;Rate of abnormal sensory nerve action potential amplitude;Rate of abnormal F wave;Rate of abnormal sympathetic skin response;

Countries

China

Contacts

Public ContactDan Wang

First Affiliated Hospital of Kunming Medical University

357278041@qq.com+86 15877933536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026